Akèy › Kansè pwostat › Virginia › Charlottesville
Etid klinik pou Kansè pwostat nan Charlottesville, VA
15 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Charlottesville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Sentara Martha Jefferson Hospital, Charlottesville
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- University of Virginia Health System ( Site 0054), Charlottesville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- University of Virginia Comprehensive Cancer Center, Charlottesville
- University of Virginia, Charlottesville
- UVA Health Cancer Care Pantops, Charlottesville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Virginia, Charlottesville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- University of Virginia Comprehensive Cancer Center, Charlottesville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Ap rekriteFaz 1/2
- University of Virginia, Charlottesville
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
Ap rekrite
- University of Virginia Health System, Charlottesville
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- University of Virginia, Charlottesville
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
Ap rekrite
- University of Virginia, Charlottesville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- University of Virginia Cancer Center, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Charlottesville
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Charlottesville
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi16 etid
- Kansè (tout kalite)13 etid
- Kansè Endomèt13 etid
- Kansè Metastatik13 etid
- Kansè poumon13 etid
- Ensifizyans kadyak12 etid
- Kansè kolorektal10 etid
- Kansè ovè10 etid
- Dyabèt tip 19 etid
- Kansè nan tete9 etid
- Kansè pankreyas9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.